Table 1.

Relationship between SYNPO2 expression and cancers

Types of cancer	Treatment	SYNPO2	Signaling pathway	Biological function
Prostate cancer	SYNPO2 inactivation and deletion	Low	NA	Clinical relapse [3, 67]
	Overexpression	Up	Interaction with zyxin	Inhibiting tumor growth and metastasis [9]
			NA	To promote lamellipodia formation and cell migration [10, 18]
	siSYNPO2	Low	NA	Inhibiting invasion and motility [65, 66]
	Phosphorylation of SYNPO2	NA	NA	Cell growth and motility [23]
Neuroblastoma	DKK1 induce SYNPO2 expression	Up	NA	Growth suppressive effect [5]
Hepatocellular carcinoma	Cytoplasmic translocation	Low	CaN/SYNPO2/F-actin axis	Metastasis [6]
Cervical cancer	miRNAs downregulated SYNPO2	Low	ER;PI3K/AKT;EMT signaling pathway	Inhibiting DNA damage and cell cycle [7]
Colorectal cancer	Overexpression	Up	YAP-KLF5 axis [47]; FOS [8]	Inhibiting proliferation and migration [47]; Inhibiting cell proliferation [8]
	Down-regulation of SYNPO2	Low	ER, PI3K/AKT, EMT signaling pathway	Inhibiting DNA damage and cell cycle [7]
	Azacitidine	Low	NA	Associated with tumor stage and survival [58]
Melanoma	Methylation	Low	NA	Recurrence [13]
	Endogenous	Low	TME	Anti-PD-1 therapy [56]
Kidney cancer	Methylation	Low	NA	Distant metastasis and survival [14]
Triple negative breast cancer	Overexpression [45, 51]; vitamin C [46]	Up	YAP/TAZ [45]; PI3K/Akt/mTOR pathway [51]; YAP1 [46]	Inhibiting stem cell-like properties, clinical stage, survival, lymph node metastasis [45, 46, 51];
	LncRNA	Low	NA	Inhibiting relapse-free survival of TNBC [12]
Bladder cancer	Methylation	Low	NA	Associated with tumor stage and tumor grade [59, 60]
	Endogenous	Low	NA	Inhibiting survival and an increased recurrence rate [11]